Canadian Cancer Trials Group Bulletins

Trial Management Group

Permanent Trial Closure

Three trials have recently been permanently closed:

Canadian Cancer Trials Group CX.4 (GOG 0191): Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/L with Erythropoietin versus Above 100 g/L without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer


Canadian Cancer Trials Group LY.11 (S9704): A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy plus Rituximab for CD20+B-Cell Lymphomas (with Possible Late Autologous Stem Cell Transplant)for Patients with Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate/High Risk International Classification Prognostic Groups


Canadian Cancer Trials Group BR.23 (S0220): A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumours)

Please note that these trials no longer require action, including the cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals. Any documentation submitted to Canadian Cancer Trials Group for these trials will not be accepted and will be returned to sites.

Health Canada, NCI US, intergroup collaborators and industry partners have been notified of this final trial closure. Centres should notify their REB of any outstanding ethics documents and of the final completion of this trial. A copy of this notification must be kept on file at your centre for auditing purposes. Please note that this memorandum supersedes any protocol instructions requiring the continued follow-up of patients and submission of data.

For complete information, please visit the "Permanent Trial Closure" area of the members area here:, as well notification is posted on each trial page.